NeuroPace Halves as Guidance Cut and Q3 Revenue Miss Hit Largest Accounts
NPCE is trading near its 52-week low of $5.46 (8.4% above the low) on elevated volume (16× avg).
Summary
Shares fell 52% to $5.83 late Friday morning, extending the year-to-date decline to 62%, after NeuroPace cut full-year 2026 revenue guidance to $91-92 million from $99.5-101.5 million. The cut follows Q3 revenue of $23.1 million, down from $23.4 million a year earlier and well short of the $27.1 million FactSet consensus. CEO Joel Becker attributed the shortfall to isolated issues concentrated in several of the company's largest accounts, compounded by field organization changes that caused more disruption than anticipated. The Q3 loss was $3.3 million, or 10 cents a share, versus 11 cents expected, so the miss is a revenue and account-concentration problem rather than a cost problem. The 10-Q filed Nov 12 shows $49.2 million of cash against $59.2 million of debt, leaving limited cushion if the account issues persist into Q4.
At the time of this announcement, NPCE was trading at $5.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $412.6M. The 52-week trading range was $5.46 to $19.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.